Literature DB >> 7852189

Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.

M Fujita1, T Enomoto, M Inoue, O Tanizawa, M Ozaki, J M Rice, T Nomura.   

Abstract

To clarify the role of the p53 tumor suppressor gene in the development of human ovarian epithelial tumors and to study the association of p53 alterations with K-ras activation, a series of 70 common epithelial ovarian tumors from Japanese patients was studied. These included 31 serous adenocarcinomas, 12 mucinous adenocarcinomas, 5 mucinous tumors of borderline malignancy, 13 endometrioid adenocarcinomas, and 9 clear cell carcinomas. Allelic loss, recognized at the polymorphic site in codon 72 of the p53 gene, was detected in 14 of 36 (39%) informative cases by restriction fragment length polymorphism analysis and by single-strand conformation polymorphism (SSCP) analysis of polymerase chain reaction (PCR)-amplified DNA fragments. Mutations in the highly conserved regions of the p53 gene were detected by SSCP analysis of PCR-amplified fragments. Mutations were found in 22 of 70 (31%) ovarian tumors, including 1 of 5 mucinous tumors of borderline malignancy. Mutations were subsequently characterized by direct sequencing. Single missense base substitutions were detected in 13 ovarian carcinomas and in one case of mucinous tumor of borderline malignancy. Short (1-8 bp) deletions and insertions were found in 8 cases. Mutations in the p53 gene occurred more frequently in serous adenocarcinomas (14/31, 45%) than in all nonserous types of malignant epithelial tumors combined (7/34, 21%; P = 0.032). Point mutations in K-ras were identified by dot blot hybridization analysis of PCR-amplified fragments with mutation-specific oligonucleotides and by direct sequencing. The overall frequency of K-ras mutations was 19/70 (27%). K-ras mutations were found in 12 of 17 (71%) mucinous tumors (8/12 mucinous carcinomas [67%] and 4/5 mucinous tumors of borderline malignancy [80%]), and occurred more frequently than in serous carcinomas (4/31, 13%; P = 0.00009) or in all nonmucinous types of ovarian epithelial tumors combined (7/53, 13%; P = 0.00002). These data suggest that different combinations of oncogenes and/or tumor suppressor genes may be involved in the genesis and development of histologically distinct categories of common epithelial tumors of the human ovary.

Entities:  

Mesh:

Year:  1994        PMID: 7852189      PMCID: PMC5919385          DOI: 10.1111/j.1349-7006.1994.tb02937.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  47 in total

1.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

2.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

Authors:  S J Baker; A C Preisinger; J M Jessup; C Paraskeva; S Markowitz; J K Willson; S Hamilton; B Vogelstein
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

Review 3.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

4.  p53 mutations in ovarian cancer: a late event?

Authors:  R Mazars; P Pujol; T Maudelonde; P Jeanteur; C Theillet
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

5.  Allelic loss on chromosome 17 in human ovarian cancer.

Authors:  N Phillips; M Ziegler; B Saha; F Xynos
Journal:  Int J Cancer       Date:  1993-04-22       Impact factor: 7.396

6.  p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus.

Authors:  V Sundaresan; P Ganly; P Hasleton; R Rudd; G Sinha; N M Bleehen; P Rabbitts
Journal:  Oncogene       Date:  1992-10       Impact factor: 9.867

7.  Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.

Authors:  S C Mok; D A Bell; R C Knapp; P M Fishbaugh; W R Welch; M G Muto; R S Berkowitz; S W Tsao
Journal:  Cancer Res       Date:  1993-04-01       Impact factor: 12.701

8.  K-ras activation in premalignant and malignant epithelial lesions of the human uterus.

Authors:  T Enomoto; M Inoue; A O Perantoni; G S Buzard; H Miki; O Tanizawa; J M Rice
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

9.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

Authors:  A Berchuck; A Kamel; R Whitaker; B Kerns; G Olt; R Kinney; J T Soper; R Dodge; D L Clarke-Pearson; P Marks
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

10.  p53 gene mutations and protein accumulation in human ovarian cancer.

Authors:  J Kupryjańczyk; A D Thor; R Beauchamp; V Merritt; S M Edgerton; D A Bell; D W Yandell
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

View more
  12 in total

1.  Somatic mutations of the PPP2R1B candidate tumor suppressor gene at chromosome 11q23 are infrequent in ovarian carcinomas.

Authors:  R Wu; D C Connolly; X Ren; E R Fearon; K R Cho
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

Review 2.  Role of p53 and Rb in ovarian cancer.

Authors:  David C Corney; Andrea Flesken-Nikitin; Jinhyang Choi; Alexander Yu Nikitin
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

3.  Stanniocalcin 1 and ovarian tumorigenesis.

Authors:  Guangzhi Liu; Gong Yang; Bin Chang; Imelda Mercado-Uribe; Miao Huang; Jingfang Zheng; Robert C Bast; Sue-Hwa Lin; Jinsong Liu
Journal:  J Natl Cancer Inst       Date:  2010-05-18       Impact factor: 13.506

4.  Establishment and characterization of a cell-line originated from human mucinous cystadenocarcinoma of the ovary.

Authors:  Sojiro Sato; Yoichi Kobayashi; Yoshiaki Okuma; Haruhiro Kondo; Yosuke Kanishi; Kaoru Saito; Kazusige Kiguchi
Journal:  Hum Cell       Date:  2002-09       Impact factor: 4.174

5.  Loss of DNA mismatch repair protein hMSH6 in ovarian cancer is histotype-specific.

Authors:  Qihui Jim Zhai; Daniel Gustavo Rosen; Karen Lu; Jinsong Liu
Journal:  Int J Clin Exp Pathol       Date:  2008-01-31

6.  Loss of heterozygosity on chromosome 6q27 and p53 mutations in epithelial ovarian cancer.

Authors:  M Suzuki; S Saito; Y Saga; M Ohwada; I Sato
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

7.  Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor development.

Authors:  Chengquan Zhao; Lee Shu-Fune Wu; Ross Barner
Journal:  J Cancer       Date:  2011-02-21       Impact factor: 4.207

8.  Potential markers for detection and monitoring of ovarian cancer.

Authors:  Brandon J D Rein; Sajal Gupta; Rima Dada; Joelle Safi; Chad Michener; Ashok Agarwal
Journal:  J Oncol       Date:  2011-04-11       Impact factor: 4.375

9.  Increased microvessel density in mucinous compared with malignant serous and benign tumours of the ovary.

Authors:  M Orre; M Lotfi-Miri; P Mamers; P A Rogers
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

10.  High resolution melting for mutation scanning of TP53 exons 5-8.

Authors:  Michael Krypuy; Ahmed Ashour Ahmed; Dariush Etemadmoghadam; Sarah J Hyland; Anna DeFazio; Stephen B Fox; James D Brenton; David D Bowtell; Alexander Dobrovic
Journal:  BMC Cancer       Date:  2007-08-31       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.